Regeneron Pharmaceuticals, Inc. (LON: 0R2M)
London
· Delayed Price · Currency is GBP · Price in USD 687.82
+2.15 (0.31%)
Jan 22, 2025, 7:07 PM BST
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.72B USD in the quarter ending September 30, 2024, with 10.65% growth. This brings the company's revenue in the last twelve months to $13.85B, up 5.72% year-over-year. In the year 2023, Regeneron Pharmaceuticals had annual revenue of $13.12B with 7.76% growth.
Revenue (ttm)
$13.85B
Revenue Growth
+5.72%
P/S Ratio
n/a
Revenue / Employee
$1.03M
Employees
13,450
Market Cap
59.41B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | 6.56B | 1.41B | 27.44% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 38.20B |
| GSK plc | 31.31B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| ConvaTec Group | 1.74B |
| Hikma Pharmaceuticals | 2.39B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |
Regeneron Pharmaceuticals News
- 13 hours ago - Robbins LLP Reminds REGN Shareholders to Seek Counsel for the Regeneron Pharmaceuticals, Inc. Class Action - PRNewsWire
- 14 hours ago - Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky - Accesswire
- 15 hours ago - ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN - GlobeNewsWire
- 17 hours ago - Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN - Accesswire
- 17 hours ago - REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewsWire
- 19 hours ago - Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky - Accesswire
- 19 hours ago - ROSEN, NATIONAL TRIAL LAWYERS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN - Accesswire
- 19 hours ago - Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report– Hagens Berman - GlobeNewsWire